Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON

VIR BIOTECHNOLOGY, INC.

(VIR)
  Report
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2021 Financial Results on August 5, 2021

07/22/2021 | 04:06pm EDT

SAN FRANCISCO, July 22, 2021 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2021 on Thursday, August 5, 2021.

The update will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.

About Vir Biotechnology
Vir Biotechnology is a clinical-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B virus, influenza A and human immunodeficiency virus. For more information, please visit www.vir.bio.


Contacts:

Investors
Heather Rowe Armstrong
VP, Investor Relations
harmstrong@vir.bio
+1-415-915-4228

Media
Cara Miller
VP, Corporate Communications
cmiller@vir.bio
+1-415-941-6746

Primary Logo


© GlobeNewswire 2021
All news about VIR BIOTECHNOLOGY, INC.
10/21VIR BIOTECHNOLOGY : to Provide Corporate Update and Report Third Quarter 2021 Financial Re..
GL
10/21Vir Biotechnology to Provide Corporate Update and Report Third Quarter 2021 Financial R..
GL
10/20INSIDER SELL : Vir Biotechnology
MT
10/15VIR BIOTECHNOLOGY : Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepte..
GL
10/15Vir Biotechnology, Inc. Announces Multiple Abstracts Highlighting New Hepatitis B Data ..
CI
10/11AstraZeneca antibody cocktail study shows success treating COVID-19
RE
10/08Govt to control distribution of GSK/Vir COVID-19 antibody in U.S. - FDA
RE
10/08VIR BIOTECHNOLOGY : FDA Says Distribution Of Authorized Sotrovimab Will Be Controlled By U..
RE
10/06VIR BIOTECHNOLOGY : to Participate in the H. C. Wainwright 2nd Annual Hepatitis B Virus (H..
GL
10/04GLAXOSMITHKLINE : GSK to supply 10,000 doses of COVID-19 drug to Canada
RE
More news
Analyst Recommendations on VIR BIOTECHNOLOGY, INC.
More recommendations
Financials (USD)
Sales 2021 456 M - -
Net income 2021 -97,0 M - -
Net cash 2021 692 M - -
P/E ratio 2021 -53,4x
Yield 2021 -
Capitalization 5 252 M 5 252 M -
EV / Sales 2021 10,0x
EV / Sales 2022 9,23x
Nbr of Employees 367
Free-Float 86,9%
Chart VIR BIOTECHNOLOGY, INC.
Duration : Period :
Vir Biotechnology, Inc. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends VIR BIOTECHNOLOGY, INC.
Short TermMid-TermLong Term
TrendsBearishBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 8
Last Close Price 40,21 $
Average target price 68,14 $
Spread / Average Target 69,5%
EPS Revisions
Managers and Directors
George A. Scangos President, Chief Executive Officer & Director
Howard Horn CFO, Secretary & Principal Accounting Officer
Vicki L. Sato Non-Executive Chairman
Michael E. Kamarck Chief Technology Officer
Phil Pang Chief Medical Officer
Sector and Competitors
1st jan.Capi. (M$)
VIR BIOTECHNOLOGY, INC.50.15%5 252
MODERNA, INC.212.57%131 807
LONZA GROUP AG32.74%61 177
IQVIA HOLDINGS INC.43.38%49 092
SEAGEN INC.-2.12%31 189
CELLTRION, INC.-38.86%25 455